[Articles] Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Pembrolizumab is a promising treatment option in patients with thymic carcinoma. Because severe autoimmune disorders are more frequent in thymic carcinoma than in other tumour types, careful monitoring is essential.

Source: The Lancet Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire, Bhaskar Kallakury, Joeffrey J Chahine, Maria Manning, Robin Mogg, Wendy M Blumenschein, Ming T Tan, Deepa S Subramaniam, Stephen V Liu, Ian M Kaplan, Justine N McCutcheon Tags: Articles Source Type: research